Polio Vaccination Guidelines

Introduction to Polio Vaccination

The Centers for Disease Control and Prevention (CDC) recommends exclusive use of Inactivated Poliovirus Vaccine (IPV) for all routine childhood polio vaccination, with a 4-dose schedule at ages 2, 4, 6-18 months, and 4-6 years, to eliminate vaccine-associated paralytic poliomyelitis (VAPP) 1, 2
The American Academy of Pediatrics (AAP) and CDC policy was implemented to eliminate VAPP, which occurred at a rate of approximately 1 case per 2.4 million Oral Poliovirus Vaccine (OPV) doses distributed 1

The CDC recommends that children who begin vaccination with IPV should complete the entire series with IPV, as IPV eliminates the risk of VAPP entirely while maintaining high individual protection 2
IPV and OPV can be used interchangeably to complete a vaccination series when necessary, as both vaccines induce protective antibody levels (>95% seroconversion) after a complete primary series, according to the CDC and World Health Organization (WHO) 3, 4
The minimum intervals between doses remain the same regardless of vaccine type previously received: 4 weeks between doses 1-2 and 2-3, and 6 months between doses 3-4, as recommended by the CDC 2

The CDC identifies only three specific circumstances where OPV may be used after IPV initiation: outbreak control settings, imminent travel to endemic areas, and parental refusal of injections, with the goal of preventing polio outbreaks and protecting high-risk populations 3, 5
OPV is the vaccine of choice for mass vaccination during polio outbreaks, even in populations previously vaccinated with IPV, due to its superior intestinal immunity and higher single-dose seroconversion rates, as recommended by the WHO and CDC 3, 4, 6

OPV should never be given to immunocompromised individuals, persons receiving immunosuppressive therapy, household contacts of immunocompromised individuals, or anyone in families with a known history of immunodeficiency, due to the risk of VAPP and other adverse events, as recommended by the CDC and WHO 7, 8
IPV eliminates the risk of VAPP entirely while maintaining high individual protection, and is safe for immunocompromised patients and their contacts, making it the preferred choice for routine vaccination, according to the CDC and AAP 1, 2, 7

Both IPV and OPV induce protective immunity in >95% of recipients after a complete primary series, with three doses of either vaccine inducing protective antibody levels (neutralizing antibody titers >1:8) to all three poliovirus serotypes, as demonstrated by studies and recommended by the CDC and WHO 4, 9
Do not switch to OPV simply to reduce injection burden, unless parents absolutely refuse injections and only for doses 3-4, and do not use OPV in any immunocompromised patient or their household contacts, even if the series was started with IPV, to minimize the risk of VAPP and other adverse events, as recommended by the CDC and WHO 3, 5, 7